Switch theme
Sign up to access all valuation multiples
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
2016
111
LTM Revenue $3.5M
LTM EBITDA -$212M
$157M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cullinan Therapeutics has a last 12-month revenue (LTM) of $3.5M and a last 12-month EBITDA of -$212M.
In the most recent fiscal year, Cullinan Therapeutics achieved revenue of n/a and an EBITDA of -$197M.
Cullinan Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cullinan Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$212M | XXX | -$197M | XXX | XXX | XXX |
| EBITDA Margin | -5984% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$212M | XXX | -$197M | XXX | XXX | XXX |
| EBIT Margin | -5970% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$185M | XXX | -$167M | XXX | XXX | XXX |
| Net Margin | -5226% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Cullinan Therapeutics's stock price is $8.
Cullinan Therapeutics has current market cap of $459M, and EV of $157M.
See Cullinan Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $157M | $459M | XXX | XXX | XXX | XXX | $-3.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Cullinan Therapeutics has market cap of $459M and EV of $157M.
Cullinan Therapeutics's trades at n/a EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Cullinan Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cullinan Therapeutics has a P/E ratio of -2.5x.
See valuation multiples for Cullinan Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $459M | XXX | $459M | XXX | XXX | XXX |
| EV (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV/Revenue | 44.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCullinan Therapeutics's last 12 month revenue growth is 447%
Cullinan Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Cullinan Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cullinan Therapeutics's rule of X is -4867% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cullinan Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 447% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -5984% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4867% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cullinan Therapeutics acquired XXX companies to date.
Last acquisition by Cullinan Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cullinan Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cullinan Therapeutics founded? | Cullinan Therapeutics was founded in 2016. |
| Where is Cullinan Therapeutics headquartered? | Cullinan Therapeutics is headquartered in United States of America. |
| How many employees does Cullinan Therapeutics have? | As of today, Cullinan Therapeutics has 111 employees. |
| Who is the CEO of Cullinan Therapeutics? | Cullinan Therapeutics's CEO is Mr. Nadim Ahmed. |
| Is Cullinan Therapeutics publicy listed? | Yes, Cullinan Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cullinan Therapeutics? | Cullinan Therapeutics trades under CGEM ticker. |
| When did Cullinan Therapeutics go public? | Cullinan Therapeutics went public in 2021. |
| Who are competitors of Cullinan Therapeutics? | Similar companies to Cullinan Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cullinan Therapeutics? | Cullinan Therapeutics's current market cap is $459M |
| What is the current revenue of Cullinan Therapeutics? | Cullinan Therapeutics's last 12 months revenue is $3.5M. |
| What is the current revenue growth of Cullinan Therapeutics? | Cullinan Therapeutics revenue growth (NTM/LTM) is 447%. |
| What is the current EV/Revenue multiple of Cullinan Therapeutics? | Current revenue multiple of Cullinan Therapeutics is 44.2x. |
| Is Cullinan Therapeutics profitable? | Yes, Cullinan Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cullinan Therapeutics? | Cullinan Therapeutics's last 12 months EBITDA is -$212M. |
| What is Cullinan Therapeutics's EBITDA margin? | Cullinan Therapeutics's last 12 months EBITDA margin is -5984%. |
| What is the current EV/EBITDA multiple of Cullinan Therapeutics? | Current EBITDA multiple of Cullinan Therapeutics is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
